Iselin NJ, November 6, 2006 – Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2006. The Company recorded a net loss of $4.2 million, or $0.22 per share, for the third quarter 2006, compared to a net loss of $3.3 million, or $0.17 per share, in the 2005 third quarter. Cash and short-term investments totaled $35.3 million at September 30, […]
Iselin NJ, October 27, 2006 – Pharmos Corporation (Nasdaq: PARS), which recently completed the acquisition of Vela Pharmaceuticals Inc. (Vela), announced today that President and COO Alan L. Rubino will present at the C.E. Unterberg, Towbin Life Sciences Conference on Tuesday, October 31, 2006 at 3:30 PM Eastern Time. The conference is taking place October 30 through October 31, 2006 at the Palace Hotel in New […]
Company Completes Vela Acquisition Following Annual Meeting of Shareholders Vela Transaction Expands Pipeline, Board and Management Team Iselin NJ, October 25, 2006 – Pharmos Corporation (Nasdaq: PARS)2 announced that at the Company’s Annual Meeting of Shareholders held this morning, Pharmos shareholders approved all proposals put to shareholder vote including: the issuance of shares of Pharmos’ common stock in connection with the proposed acquisition of Vela […]
Seasoned Biotechnology Industry Financial Executive Iselin NJ, October 5, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today the appointment of S. Colin Neill as Senior Vice President, Chief Financial Officer, Secretary, and Treasurer. Mr. Neill will be located at Pharmos’ Iselin, New Jersey headquarters. Haim Aviv, Ph.D., Chairman and CEO, said, “We are pleased to welcome Colin to the Pharmos management team and believe that […]
Former Dissident Pharmos Shareholder Now Supports Acquisition Iselin NJ, September 5, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that it has signed a definitive agreement that includes revised terms for the acquisition of Vela Pharmaceuticals Inc. (Vela). The number of shares of Pharmos common stock to be issued to Vela shareholders at closing has been reduced from 11.5 million shares to 6.5 million shares […]
CB2-Selective Compounds and Pending Vela Acquisition Driving Pipeline Iselin NJ, August 10, 2006 – – Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2006. Cash and short-term investments totaled $39.4 million at June 30, 2006. The Company recorded a net loss of $4.1 million, or $0.21 per share, for the second quarter 2006 compared to a net loss of $3.3 […]
Iselin NJ, August 10, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that it has commenced dosing in a second Phase 2a clinical study of cannabinor (PRS-211,375) for the treatment of pain. The proof-of-concept trial will test for analgesic activity and the safety of cannabinor, a CB2-selective synthetic cannabinoid drug candidate, in healthy subjects experiencing capsaicin-induced pain. The Company also noted that patient enrollment continues in […]
Iselin NJ, July 12, 2006 Pharmos Corporation (Nasdaq: PARS) announced an expansion of its corporate web site at www.pharmoscorp.com to provide detailed information regarding the Company’s proposed acquisition of Vela Pharmaceuticals, Inc. (Vela). Since a significant portion of its shareholders reside in Israel, the initiative includes a new Hebrew-translated site at www.pharmos.com. Pharmos shareholders and other investors interested in learning about the Company, and specifically its pending acquisition […]
Additional Phase 2a Study in Neuropathic Pain Scheduled for Third Quarter Further Pipeline Growth Planned with Pending Vela Acquisition Iselin NJ, June 29, 2006 – Pharmos Corporation (Nasdaq: PARS), which recently entered into a definitive agreement to acquire Vela Pharmaceuticals Inc. (Vela), announced today that it has commenced dosing for its Phase 2a clinical study of cannabinor (PRS-211,375), a CB2-selective synthetic cannabinoid drug candidate for the […]
Iselin NJ, June 20, 2006 Pharmos Corporation (Nasdaq: PARS) announced today the Company has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the local Ethics Committee in the U.K. to commence a Phase 2a clinical study of cannabinor (PRS-211,375), a CB2-selective synthetic cannabinoid drug candidate for the treatment of pain. The proof-of-concept trial will be conducted among healthy subjects experiencing pain […]